Applied Genetic Technologies (NASDAQ:AGTC) has announced it has reached two milestones in two of its Phase 1/2 clinical trials. As quoted in the press release: The company completed enrollment of the dose escalation portion of the achromatopsia (ACHM) CNGB3 trial, which is evaluating the safety and efficacy of its product candidate (rAAV2tYF-PR1.7-hCNGB3) for the treatment … Continued
The post Applied Genetic Technologies Announces Enrollments in Phase 1/2 Clinical Trials appeared first on Investing News Network.